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httpcense.Abstract Introduction: The rise in human immune virus infections (HIV) and the neglect of tuber-
culosis (TB) control programs have enabled a resurgence of TB. The emergence of drug-resistant
strains has also contributed to this new epidemic from 2000 to 2004, with, 20% of TB cases being
resistant to standard treatments and 2% resistant to second-line drugs. The rate at which new TB
cases occur varies widely, even in neighboring countries, apparently because of differences in health
care systems.
Aim of the work: The aim of the current study is to investigate susceptibility to anti-TB drugs in
newly diagnosed and old TB patients (with persistent positive sputum smear after 2 months of anti-
TB treatment) for detecting multi-drug resistance (MDR-TB) and extensively drug resistant TB
(EDR-TB). As well, ﬁnd out risk factors associated with the development of MDR and XDR-TB.
Patients and methods: The study included 40 strains of mycobacterium TB. These strains were
divided into two groups: Group I: 20 strains isolated from new cases (patients who had never trea-
ted for TB or who have taken anti TB drugs for less than 1 month). Group II: 20 strains isolated
from old cases (Patients with persistent positive sputum smear after 2 months of anti-TB treatment).
After taking an informed consent, all subjects were subjected to: Detailed history taking, complete
clinical examination, anthropometric measurements, routine laboratory investigations, erythrocyte
sedimentation rate (ESR), chest X-ray, microbiological investigations (including, direct microscopy
examination, isolation and identiﬁcation of mycobacterium TB, and testing sensitivity for anti-TB
drugs).(A.A. El Ganady).
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636 S.A. Hafez et al.Results: MDR and XDR TB were more common among TB patients with persistent positive
sputum despite anti TB treatment than newly diagnosed cases. Diabetes mellitus (DM), HIV and
anemia were considered to be other risk factors for MDR-TB and XDR-TB. Management of
MDR-TB and XDR TB is a challenge which should be undertaken by experienced clinicians at cen-
ters equipped with reliable laboratory service for mycobacterial culture and in vitro sensitivity test-
ing as it requires prolonged use of expensive second-line drugs with a signiﬁcant potential for
toxicity.
Conclusion: Emergence of MDR-TB and XDR TB has the potential to be a serious public health
problem in Egypt and that strengthened TB control and improved monitoring of therapy is needed.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Tuberculosis has been present in humans since antiquity.
Tubercular decay has been found in the spines of mummies
from 3000 to 2400 BC. Phthisis is a Greek term for TB;
Around 460 BC, Hippocrates identiﬁed phthisis as the most
widespread disease of the times involving coughing up blood
and fever, which was almost always fatal [1]. The bacillus
causing TB, was identiﬁed and described on 24 March 1882
by Robert Koch. He received the Nobel Prize in physiology
and medicine in 1905 for this discovery [1]. Koch did not be-
lieve that bovine and human TB were similar, which delayed
the recognition of infected milk as a source of infection. La-
ter, this source was eliminated by the pasteurization process.
Koch announced a glycerin extract of the tubercle bacilli as a
remedy for TB in 1890, calling it ‘‘tuberculin’’. It was not
effective, but was later adapted as a test for pre symptomatic
TB [1].
Early diagnosis and immediate initiation of treatment are
essential for an effective TB control program. Delay in
diagnosis is signiﬁcant to both disease prognosis at the individ-
ual level and transmission within the community. Most trans-
missions occur between the onset of cough and initiation of
treatment [2]. The diagnosis of pulmonary TB depends on clin-
ical suspicion, response to treatment, chest radiographs, stain-
ing for acid fast bacilli (AFB), culture for TB, and, nucleic acid
ampliﬁcation (NAA) assays [2].
Despite many advances in the diagnosis of TB in recent
years, sputum smear testing using the Ziehl–Nielsen stain
(ZN) is still the basic tool for TB diagnosis and monitoring
because it is a quick, simple, and low cost test that can be
reproduced in any setting and used to detect infectious cases
in the community, a task that constitutes the cornerstone of
TB diagnosis and monitoring [3].
Although culture has always been considered to be the gold
standard technique for the diagnosis of TB, the result may be
negative in some smear-positive patients owing to the loss of
viability of the bacilli or the process used to decontaminate
the sample. Likewise, false positive results may arise because
of contamination of specimens in the laboratory. Despite these
limitations, culture still plays a key role in the diagnosis and
management of TB [4].
Anti TB treatment has two main objectives. First, there is a
need to rapidly kill those AFB living extracellular in lung cav-
ities, which are metabolically active and are dividing continu-
ously; this is required in order to attain the negativization of
sputum and therefore to prevent further transmission of thedisease. Second, it is necessary to achieve complete sterilization
and elimination of those AFB replicating less actively in acidic
and anoxic closed lesions, and to kill semi dormant AFB living
intracellular in other host tissues, otherwise these bacilli may
persist and will be responsible for subsequent TB relapses.
These reasons, along with the prevention of drug resistance,
support the use of a combination therapy for the treatment
of TB [5].
Several risk factors have been identiﬁed in the causation of
drug resistant TB, of which the three most important are pre-
vious treatment with anti-TB drugs which may be inappropri-
ate, incomplete or erratic, high prevalence of drug resistant TB
in the community and contact with a patient known to have
drug resistant TB. In patients with previous treatment or dis-
ease, the odds of resistant TB were 4–7 times higher than for
persons with no history of past treatment. However, standard-
ized short course chemotherapy carries only a minimal risk of
emergence of MDR-TB [6]. Other factors that may be respon-
sible for increased risk of resistant TB are: co-infection with
HIV, socioeconomically deprived groups in slums, prisons,
correctional facilities, day care centers, intravenous drug abus-
ers and other immunocompromised states as in transplant
recipients, anti-cancer therapy patients, and patients with
DM. Radio logically far advanced pulmonary TB patients
with cavitary lesions were 4 times as likely to harbor drug resis-
tant organisms [6].
Multidrug-resistant tuberculosis is deﬁned as infection
caused by mycobacterium TB resistant to isoniazid and
rifampin. EDR- TB was deﬁned initially as infection caused
by mycobacterium TB not only resistant to isoniazid and
rifampin but also to at least 3 of the 6 classes of second-line
agents approved for the treatment of TB (aminoglycosides,
polypeptides, ﬂuoroquinolones, thioamides, cycloserine, and
para-aminosalicyclic acid) [7]. The World Health Organiza-
tion (WHO) Global Task Force on XDR-TB modiﬁed the
deﬁnition in October 2006 following the report of the out-
break in KwaZulu Natal. Because drug susceptibility testing
is reliable only for amikacin, kanamycin, capreomycin, and
ﬂuoroquinolones among the second-line agents, the deﬁnition
of EDR-TB is now resistance to isoniazid and rifampin in
addition to resistance to any ﬂuoroquinolone and any of
the second-line injectable drugs: amikacin, kanamycin, and
capreomycin [8].
The primary aim in the control of MDR-TB is to prevent its
development in the ﬁrst place. This can be done by Directly
Observed Treatment Short Course (DOTS), which is the most
cost effective way of treatment and prevention of MDR-TB.
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short course chemotherapy, careful introduction of reserve
drugs to treat MDR cases to reduce further transmission of
such strains will be required [9].
There is a need for revision of guidelines of national pro-
grams based on levels of resistance, training of professionals
in private sector, strengthening of existing National TB Con-
trol Program, restricting use of rifampicin, taking logistic mea-
sures to ensure regular supply of drugs at all levels of National
TB Control Program and by ensuring compliance enhancing
measures like providing free anti-TB drugs, supervised treat-
ment and health education [10].Aim of the work
The aim of the current study is to investigate susceptibility
to anti-TB drugs (including some of the 1st and 2nd
drugs) in newly diagnosed and old TB patients (with per-
sistent positive sputum smear after 2 months of anti-TB
treatment) for detecting MDR and EDR-TB. As well, ﬁnd
out risk factors associated with the development of MDR
and XDR-TB.Subjects
The study will include 40 strains of TB isolated from new and
old patients suspected clinically and radio logically as pulmon-
ary TB. These strains were divided into Group I: 20 strains iso-
lated from new cases (patients who had never treated for TB or
who have taken anti TB drugs for less than 1 month). Group
II: 20 strains isolated from old cases (Patients with persistent
positive sputum smear after 2 months of anti-TB treatment).
The patients were collected from Maemora chest hospital dur-
ing the period between February and September 2010 for
detecting EDR-TB.
Inclusion criteria:
1. Age P15 years.
2. Positive for AFB.
3. All patients with pulmonary TB.
Exclusion criteria:
1. Atypical mycobacterium TB.
2. Extra pulmonary TB.
Methods
After taking an informed consent, all subjects were subjected
to:
1. Detailed history taking.
2. Complete clinical examination.
3. Anthropometric measurements.
4. Routine laboratory investigations including complete blood
picture, liver and renal functions and fasting blood glucose
level (FBS).
5. Erythrocyte sedimentation rate (ESR).6. Plain chest radiographs were examined. The patients with
active pulmonary TB were divided radio logically according
to the classiﬁcation of the National TBAssociation of the
USA into three categories [11]:
I Minimal lesions: include those of densities involving a
small part of one or both lungs but the total extent,
regardless of distribution, should not exceed the vol-
ume of the lung on one side, and they do not contain
demonstrable cavitations.
II Moderately advanced lesions: may be present in one or
both lungs, but the total extent should not exceed the
following limits:
(a) Disseminated lesions of slight to moderate density
that may extend throughout the total volume of one
lung or the equivalent to both lungs.
(b) Dense and conﬂuent lesions limited in extent to one
third the volume of one lung.
(c) Total diameter of cavitations, if present, must be less
than 4 cm.
III Far advanced lesions: Include those more extensive than
moderately advanced.
7. Microbiological investigations
Clinical samples: Three early morning sputum specimens
were collected from all cases on three successive days in
sterile containers.
Direct microscopy examination: A direct smear was pre-
pared from each selected specimen and stained by ZN
stain AFB.
Isolation of mycobacterium TB: Sputum samples were
decontaminated with Petroff’s method as follows: Equal
volume of 4%NaOH was added to each sputum sample,
incubated at 37 C with intermittent shacking, followed
by centrifugation. Supernatant was discarded and one
drop of phenol red indicator was added to the deposit
and then few drops of 8% HCl for neutralization, this
deposit was used for: preparation of another ﬁlm stained
by ZN stain.
Culture on Lowenstein-Jensen (LJ): Slope culture was
incubated at 37 C, and examined using hand lens
5–7 days after incubation, then weekly for 6–8 weeks.
Identiﬁcation of mycobacterium TB isolates: Strains that
required more than 7 days growing were further identi-
ﬁed on the basis of the following.(A) Acid fast alcohol fast staining.
(B) Colonial morphology. On LJ media.
(C) Preference growth at 35–37 C.
(D) Lack of photoreactivity.
(E) Inability to grow on media containing 500 lg/ml
paranitrobenzoic acid [12].
Testing sensitivity for anti-TB drugs: 40 strains identiﬁed
as mycobacterium TB were tested for their sensitivity
to isoniazid and rifampin and two ﬂuroroquinolones
(ciproﬂoxacin and levoﬂoxacin) and two injectable
drugs (amikacin and kanamycin) using 1% proportion
method [12].
Table 1 Frequency of the symptoms among the two studied
groups.
Group I Group II P
No. % No. %
Cough
Yes 20 100.00 20 100.00
No 0 0.00 0 0.00 –
Weight loss
Yes 15 75.00 14 70.00
No 5 25.00 6 30.00 0.723
Night sweating
Yes 14 70.00 14 70.00
No 6 30.00 6 30.00 –
Hemoptysis
Yes 6 30.00 8 40.00
No 14 70.00 12 60.00 0.507
Fever
Yes 16 80.00 16 80.00
No 4 20.00 4 20.00 –
Dyspnea
Yes 11 55.00 12 60.00
No 9 45.00 8 40.00 0.749
P is signiﬁcant at 60.05.
638 S.A. Hafez et al.(a) Concentration of the drugs in the medium: INH, amika-
cin and kanamycin were dissolved in distilled water,
while RIF was dissolved in dimethylformamide, cipro-
ﬂoxacin and levoﬂoxacin prepared from commercially
available solution for I.V infusion. They were added to
LJ medium to give the ﬁnal concentrations of: 0.2 lg/
ml for INH, 40 lg/ml for RIF, 2 lg/ml for ciproﬂoxa-
cin, 2 lg/ml for levoﬂoxacin, 30 lg/ml for amikacin,
30 lg/ml for kanamycin [12].
(b) Preparation of the bacterial suspension: With a sterile
loop about 5 mg of the culture was taken, represent-
ing different Colonies growing on the primary cul-
ture. The sample was placed in a sterile test tube
containing about 30 glass pellets 3–5 mm in diameter.
Shaking was done for 30 s, then 0.1 ml of sterile dis-
tilled water was added and the tube was shaken.
Another 5 ml of sterile distilled water was added fol-
lowed by shaking.
(c) Calibration: The bacterial suspension was then col-
lected in a sterile test tube. The opacity of the suspen-
sion was adjusted to correspond to Mc-farland
nephelometer standards no. 1 (3 · 108 organisms/ml)
by the addition of sterile distilled water. Tenfold serial
dilution (101, 102 down to 105) was made from
this stock suspension using sterile distilled water.
About 0.2 ml of 101, 103 and 105 dilutions were
inoculated on media with and without the drug.
Tubes were incubated at 37 C in a slanted position
to allow the ﬂuid to cover the whole surface of the
medium. After 24 h the tubes were placed in the
upright position.
(d) Reading the results: The tubes were inspected for bac-
terial growth after 3 weeks of incubation. If no
growth or little growth, the tubes were left for
2 weeks. The number of the colonies that appeared
in each tube was carefully counted using a hand lens.
The number of colonies on the control tube repre-
sented the number of viable bacilli contained in the
inoculum for each dilution. The number of colonies
on the drug containing medium represented the num-
ber of resistant bacilli obtained in the same inoculum.
The strain was considered resistant, if the ratio
between the number of colonies on the drug contain-
ing medium to the number of colonies on the control
was >1% [12].
Results
This study included 40 patients with clinical, radiological, and
bacteriological evidences of pulmonary TB. These strains were
divided into two groups: Group I: 20 strains isolated from new
cases (patients who have never had treatment for TB or who
have taken anti TB drugs for less than 1 month). Group II:
20 strains isolated from old cases (Patients with persistent
positive sputum smear after 2 months of anti-TB treatment).
Demographic data
Age: The mean value of age was 39.35 ± 18.08 years in group
I and 48.15 ± 16.22 years in group II. There was nostatistically signiﬁcant difference between the two studied
groups (P= 0.057).
Sex: Each of the studied groups included 14 (70%) males
and 6 (30%) females with no statistically signiﬁcant differences
between them.
Body mass index: The mean value of BMI in group I was
23.9 ± 1.21 kg/m2 and in group II was 24.28 ± 1.15 kg/m2.
No statistically signiﬁcant difference was found between the
two groups.
Clinical data
Symptoms (Table 1): demonstrates the proﬁle of symptoms
among the studied patients. Cough was the most common
symptom that was evident in all studied cases (100%),
whereas weight loss, night sweating, hemoptysis, fever,
dyspnea, were reported in (70–75%), (70%), (30–40%),
(80%), (55–60%) of the studied cases respectively. No sta-
tistically signiﬁcant difference was found between the two
groups.
Risk factors
In group I: Regarding risk factors for TB, 6 patients presented
with DM controlled on oral antidiuretic drugs, 1 with renal
insufﬁciency (blood urea 94 mg/dl and blood creatinine
2.5 mg/dl), 2 with hypertension, 1 with bronchial asthma, 1
with depression, 14 patients with anemia, 4 patients had past
positive family history for pulmonary TB, 3 patients had a his-
tory of contact with TB patients. 14 patients were in low socio-
economic state.
In group II: Regarding risk factors for TB, 6 patients pre-
sented with DM, (4 of them on oral antidiuretic drugs, 2 on
insulin therapy). 1 with renal failure, 4 with hypertension, 1
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HIV, 1 with partial deafness, 1 with drug abuse, 1 with depres-
sion and hysterectomy, 17 with anemia, 7 had past positive
family history for pulmonary TB, 6 had a history of contact
with TB patients, 10 received anti TB drugs, 5 of them cured
since more than 1 year, and 3 of them did not complete treat-
ment due to side effect of drugs and long duration of treat-
ment, 2 of them received treatment twice.
Routine laboratory investigations (Table 2)
The mean values of Hemoglobin (HB) were 10.95 ± 1.33 and
10.595 ± 2.18 g/dl in group I and group II respectively. There
was no statistically signiﬁcant difference between the two stud-
ied groups regarding HB (P= 0.271).
Regarding liver enzymes: Alanine amino transferase (ALT)
values were within the normal range in group I except in casesTable 2 Comparison between the two studied groups regard-
ing laboratory investigation.
Laboratory investigation P
Group I Group II
HB
Min 8.4 5.5
Max 13.6 14.8 0.271
Mean 10.95 10.595
SD 1.33 2.18
ALT
Min 3 4
Max 16 78 0.042
Mean 8.35 15
SD 3.72 16.32
AST
Min 4 3
Max 16 82 0.063
Mean 7.90 14.05
SD 3.84 17.12
UREA
Min 22 19
Max 94 57 0.228
Mean 35.60 32.3
SD 16.45 10.57
Creatinin
Min 0.6 0.5
Max 2.5 1.6 0.225
Mean 0.95 0.855
SD 0.43 0.31
FBS
Min 70 72
Max 119 373 0.033
Mean 94.47 134.45
SD 16.39 90.35
Bilirubin
Min 0.4 0.4
Max 1.1 1.8 0.092
Mean 0.65 0.77
SD 0.20 0.36
P is signiﬁcant at 60.05.6, 13, 19 who had increased ALT levels (14, 16, 22 U/l) respec-
tively. ALT values were within the normal range (up to 12 U/l)
in group II except in cases 4, 8, 9, 13, 16, 18 who had increased
ALT levels (24, 15, 17, 26, 32, 17 U/l) respectively. Aspartate
amino transferase AST values were within the normal range
(up to 12 U/l) in group I except in cases 6, 13, 19 who had in-
creased AST levels (15, 18, 20 U/l) respectively. AST values
were within normal range in group II except in cases 4, 8, 9,
13, 16, 18 who had increased AST levels (14, 16, 20, 28, 30,
21 U/l) respectively. The mean values of bilirubin were
0.65 ± 0.20 and 0.77 ± 0.36 mg/dl in group I and group II
respectively. There was no statistically signiﬁcant difference
(P= 0.092).
The mean values of blood urea were 35.6 ± 16.45 and
32.3 ± 10.57 mg/dl in group I and group II respectively. There
was no statistically signiﬁcant difference between the two stud-
ied groups (P= 0.228). The mean value of serum creatinine
was 0.95 ± 0.43, 0.855 ± 0.31 mg/dl for group I and group
II respectively. There was no statistically signiﬁcant difference
regarding creatinine (P= 0.225).
The mean values of FBS were 94.47 ± 16.34 and
134.45 ± 90.35 mg/dl in group I and group II respectively in
group I (cases number 2, 4, 5, 11, 14, 19 had FBS 116, 115,
118, 116, 119, 136 mg/dl respectively controlled on oral antidi-
abetic drugs,) in group II (cases number 2, 9, 13, 17, 18, 19 had
FBS 226, 373, 263, 316, 114, 203 mg/dl respectively 4 of them
on oral antidiabetic drugs 2 on insulin therapy). Group IITable 3 Showing comparison between the studied groups
regarding ESR ﬁrst and 2 h.
ESR
Group I Group II
1st 2nd 1st 2nd
1 82 112 110 142
2 96 130 95 133
3 68 112 110 138
4 85 118 95 142
5 77 121 90 135
6 92 130 120 148
7 66 111 113 138
8 86 132 150 177
9 100 132 98 145
10 92 118 60 95
11 102 142 90 130
12 110 138 76 112
13 100 132 92 136
14 104 144 87 117
15 66 96 94 140
16 102 146 91 132
17 76 103 97 130
18 72 113 89 128
19 104 142 101 141
20 68 115 78 114
Min 66 96 60 95
Max 110 146 150 177
Mean 87.40 124.35 96.80 133.65
SD 14.69 14.43 18.44 16.51
P 0.04 0.033
P is signiﬁcant at 60.05.
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those of group I (P= 0.033).
The mean values of ESR
Table 3 were 87.40 ± 14.69, 124.35 ± 14.43 in group I versus
96.80 ± 18.44, 133.65 ± 16.51 in group II. The mean value in
group II was statistically signiﬁcantly higher than those in
group I (P< 0.05).
The radiological ﬁndings (Table 4)
The radiological ﬁndings on plain X-ray chest varied from
ﬁbrosis, consolidation, cavities, cystic changes, pleural effu-
sion, and atelectasis to nodules. The most common radiologi-
cal ﬁndings were ﬁbrocystic changes and consolidation that
had been detected in 80% of the studied cases.
Concerning the frequency of the location of lesions among
the studied patients (both lungs were affected in 50% of cases,
right lung in 35%, left lung in 15%), upper lobe in 46%, mid-
dle lobe in 24%, left lobe in 9%, diffuse in 21%.
According to the classiﬁcation of the National TB Associa-
tion of the USA(30,156) regarding grading radiological extent of
pulmonary TB into three categories, minimal, moderate and
severe affection were observed in 15%, 60% and 25% of cases
in group I respectively versus 20%, 50% and 30% in group II
respectively. There was no statistically signiﬁcant difference
between the two studied groups regarding X-ray ﬁndings
(P= 0.812).
Bacteriological ﬁndings
Sputum culture and drug sensitivity Tables 5 and 6: demon-
strated ﬁndings of sputum culture and drug sensitivity using
LJ media for the 40 strains that have been isolated from the
studied cases.
Regarding drug sensitivity to rifampicin (Fig. 1): In group I
and II, 70% and 20% of the studied strains were sensitive to
rifampicin versus 30% and 80% of strains were resistant
respectively. The resistance in group II was statistically signif-
icantly higher than those in group I.
Concerning drug sensitivity to isoniazid (Fig. 2): In group I
and II, 55% and 25% of the studied strains were sensitive to
isoniazid versus 45% and 75% of strains were resistant respec-
tively. The resistance in group II was statistically signiﬁcantly
higher than those in group I.Table 4 Comparison between the two studied groups regard-
ing the severity of radiological ﬁndings.
X-ray
Group I Group II
No. % No. %
Minimal 3 15.00 4 20.00
Moderate 12 60.00 10 50.00
Severe 5 25.00 6 30.00
P 0.812
P is signiﬁcant at 60.05.As regards drug sensitivity to levoﬂoxacin (Fig. 3): In group
I and II, 90% and 80% of the studied strains were sensitive to
levoﬂoxacin versus 10% and 20% of strains were resistant
respectively. The difference was insigniﬁcant between the two
studied groups.
Regarding drug sensitivity to ciproﬂoxacin (Fig. 4): In group
I and II, 45% and 10% of the studied strains were sensitive to
ciproﬂoxacin versus 55% and 90% of strains were resistant
respectively. The resistance in group II was statistically signif-
icantly higher than those in group I.
Concerning drug sensitivity to kanamycin (Fig. 5): In group I
and II, 45% and 35% of the studied strains were sensitive to
kanamycin versus 55% and 65% of strains were resistant
respectively. The difference was insigniﬁcant between the two
studied groups.
As regards drug sensitivity to amikacin (Fig. 6): In group I
and II, 100% and 55% of the studied strains were sensitive to
amikacin versus 0% and 45% of strains were resistant respec-
tively. The resistance in group II was statistically signiﬁcantly
higher than those in group I.
Drug resistance (Table 7, Fig. 7): According to the ﬁndings
of drug sensitivity in the two studied groups, MDR-TB strains
were detected in 20% and 25% of group I and group II respec-
tively. Whereas XDR-TB was detected in 0% and 35% of
group I and group II respectively. The XDR in group II was
statistically signiﬁcantly higher than those in group I.Discussion
Treatment of MDR-TB requires prolonged and expensive che-
motherapy using second-line drugs of heightened toxicity.
Resistance to the second line drugs also arises, then the disease
becomes virtually untreatable with emergence of EDR-TB that
has been reported in all regions of the world.
The current study was carried out to investigate the suscep-
tibility to anti-TB drugs in newly diagnosed and old TB
patients. The study included 40 TB strains; they were divided
into two groups: Group I: 20 strains isolated from new cases:
Group II: 20 strains isolated from old cases.
Concerning demographic data in the present study, the
mean age of active TB patients was 48.15 ± 16.22 years. This
coincides with the previous studies that showed that the mean
age of active pulmonary TB patients ranged between 30 and
48 years [13].
In this study, active pulmonary TB was more evident
among males (70%) than females (30%). In accordance to
our ﬁnding, Hakan et al. reported that males were more
affected by active pulmonary TB than females (76%, 72%
males versus 24%, 28% females respectively) [14]. On the con-
trary Prabha et al. reported that active pulmonary TB was
higher among females (60%) than males (40%), as HIV TB pa-
tients were included in their study. With increased incidence of
HIV, male and female rates of TB infection are reversed, since
HIV more commonly affects females [15].
Regarding the medical history of the studied TB patients,
15% of patients in group I versus 30% in group II had a his-
tory of contact with TB patient. In group II, 50% of patients
previously received anti TB drugs; 35% of those patients had
relapse after treatment, 15% of patients were defaulter. Drug
resistance TB was detected in 20% and 60% of studied cases
of group I and II respectively. All 20% in group I were with
Table 5 Results of sputum culture and sensitivity to rifampicin, isoniazid and levoﬂoxacin in the two studied groups.
Rifampicin Isoniazide Levoﬂoxacin
Group I Group II Group I Group II Group I Group II
1 R R S S S S
2 S R S R R R
3 R R R R S S
4 S R R R S S
5 S R R R S S
6 S R S R S S
7 S S S R S R
8 R R R R S S
9 S S S R S S
10 S S S R S R
11 S R S R S S
12 R S R S S S
13 S R S R S S
14 R R R R R S
15 S R R R S S
16 S R R R S R
17 R R S R S S
18 S R S S S S
19 S R S S S S
20 S R R S S S
No. % No. % No. % No. % No. % No. %
R 6 30.00 16 80.00 9 45.00 15 75.00 2 10 4 20.00
S 14 70.00 4 20.00 11 55.00 5 25.00 18 90 16 80.00
P is signiﬁcant at 60.05.
Table 6 Results of sputum culture and sensitivity to ciproﬂoxacin, Kanamycin and Amikacin in the two studied groups.
Ciproﬂoxacin Kanamycin Amikacin
Group I Group II Group I Group II Group I Group II
1 R R R R S S
2 R R R R S S
3 R R S R S R
4 R R R S S S
5 S R R S S S
6 S R S R S S
7 S R S R S S
8 S R R R S R
9 S R S R S S
10 S R R R S S
11 R R R S S R
12 S R S R S S
13 S S S S S R
14 R R S S S R
15 S R S S S S
16 R R S R S R
17 R S R R S R
18 R R R R S R
19 R R R S S S
20 R R R R S R
No. % No. % No. % No. % No. % No. %
R 11 55.00 18 90.00 11 55.00 13 65.00 0 0.0 9 45.00
S 9 45.00 2 10.00 9 45.00 7 35.00 20 100 11 55.00
P is signiﬁcant at 60.05.
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and 35% with XDR-TB. Our study showed that previous anti-
TB treatment and contact with TB patients are considered as
risk factors for MDR-TB and XDR-TB.Our ﬁndings concurred with data from some series. Sharma
described that in India globally, about 3% of all newly diag-
nosed patients have MDR-TB. The proportion is higher in pa-
tients who have previously received anti TB treatment
R
30.0%
S
70.0%
Group I Group II
R
80.0%
S
20.0%
Fig. 1 Comparison between the two studied groups regarding rifampicin sensitivity.
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Fig. 2 Comparison between the two studied groups regarding Isoniazid sensitivity.
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Fig. 3 Comparison between the two studied groups regarding levoﬂoxacin sensitivity.
642 S.A. Hafez et al.reﬂecting the failure of programs designed to ensure complete
cure of patients with TB. While host genetic factors may prob-
ably contribute, incomplete and inadequate treatment is the
most important factor leading to the development of MDR-
TB [16]. Eker et al. reported that 53% of patients with
MDR-TB and 86% of patients with XDR-TB had previously
received anti-TB treatment for >1 month. Only 1 of the 7 pa-
tients with XDR-TB had previously received DOT [17].
Concerning the symptoms encountered in our studied pa-
tients, the most common presenting symptoms were cough
(100%) and fever (80%) followed by weight loss (75%), nightsweating (70%), dyspnea (60%) and hemoptysis (40%). Sup-
porting our data, Van Crevel et al. in their study demonstrated
that the TB patients presented with fever (60%), night sweats
(68%), fatigue (83%), and weight loss (80%) [10].
Regarding co-morbidities associated with pulmonary TB in
this work, 43% of patients with drug resistance TB had DM
while 20% of patients with drug sensitive TB had DM, our
ﬁndings signify that there was a signiﬁcant association between
DM and drug resistance TB. Consistent with our ﬁndings, Ba-
shar et al. studied the incidence of MDR-TB among DM and
found that MDR-TB cases were higher among those with DM
R
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Fig. 4 Comparison between the two studied groups regarding ciproﬂoxacin sensitivity.
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Fig. 5 Comparison between the two studied groups regarding kanamycin sensitivity.
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Fig. 6 Comparison between the two studied groups regarding Amikacin sensitivity.
Detection of extensively drug resistant pulmonary tuberculosis 643[18]. On the contrary Parvaneh et al. reported that history of
contact with TB patients and DM in both MDR and non
MDR-TB groups were among the insigniﬁcant variables found
in their study. DM was more common in the non MDR-TB
group (9.0% versus 6.4% in MDR-TB group). The fact that
most of these patients are refugees could be a possible riskfactor for the development of resistance due to incomplete
and irregular treatment of TB in them [19].
Regarding anemia, it was present in 100% of cases with
MDR-TB and XDR-TB, VS 63% with drug susceptible TB
cases. Some studies qualify anemia and malnutrition as risk
factors for the development of anti-TB drug adverse reactions;
Table 7 Comparison between the two studied groups regard-
ing frequency of MDR and XDR.
Group I Group II
No. % No. %
MDR 4 20.00 5 25.00
XDR 0 0.00 7 35.00
P 0.007*
P is signiﬁcant at 60.05.
644 S.A. Hafez et al.others have suggested that anemia is seen as part of the clinical
manifestation of TB and as a consequence of a chronic disease.
Other co-morbidities in our study, encountered in associa-
tion with MDR-TB and XDR-TB, were renal failure (1 case
in each group), HIV (1 case of group II) and drug abuse (2
cases of group II). An association between HIV infection
and drug-resistant TB has been reported in the United
States.(33) This association may occur because the contribution
of the immune system in eradicating bacteria during chemo-
therapy is crucial in preventing the emergence of resistance.
This may happen because the patient with HIV is unable to
contain the size of individual lesions, thus increasing the num-
ber of organisms available for mutation. Also, patients with
TB and HIV may be unable to absorb their drugs due to con-
comitant gastrointestinal disease, exposing the organisms to
sub therapeutic concentrations.
In this work ESR was signiﬁcantly higher among patients
of group II than group I. In accordance with these ﬁndings
Hakan et al. [14] showed that ESR in active pulmonary TB
group was signiﬁcantly higher than the control group and
the ESR decreased signiﬁcantly after anti TB treatment.
Concerning the extent of radiological presentation of pa-
tients with MDR-TB and XDR-TB, it has been found that
44% and 56% of cases had moderate and severe lesions in
chest X-ray respectively, while in patients with drug susceptible
TB 29%, 62% and 9% of cases had (minimal, moderate andRDM
0
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Fig. 7 Comparison between the two studiedsevere) lesion in chest X-ray respectively. Cavitary lesions rep-
resent the most common ﬁndings among drug resistant cases.
Our data signify that there is relation between severity and
type of TB lesions and liability to MDR-TB. In accordance
with our ﬁndings, Singla et al. (2003) showed that multiple cav-
itary diseases were signiﬁcant factors associated with persistent
sputum positivity at the end of 2 months of treatment, and
presence of multiple cavitary diseases, may be helpful in strat-
ifying the patients according to the risk of adverse outcome,
thus allowing greater efﬁciency in resource utilization [20].
Fawzy et al. (2005) showed that the minimal lesion was
higher in primary cases and far advanced lesion in X-ray was
higher in secondary cases [21]. Abdelazim et al. (2003) revealed
that 58% of patients with MDR-TB had far advanced lesion in
chest X-ray followed by minimal lesion in chest X-ray 26%
then moderately advanced lesion in 16% of cases [22].
Our study revealed that drug resistance to rifampicin and
Isoniazid has been encountered in both group I and group II
(in 30% versus 80% and 45% versus and75% respectively)
documenting more evidence of drug resistance among patients
of group II. Similar ﬁndings have been demonstrated by
Barnard et al. who reported a higher incidence of INH resis-
tance among patients receiving anti-TB treatment, as 27% of
MDR strains and 54% of INH monoresistant strains were de-
tected [23]. Afranio et al. demonstrated that patients with TB
strains resistant to rifampin and isoniazid were found in 6%
of patients who suffered relapse after completion of therapy,
in 33% of patients who failed to respond to the ﬁrst-line drug
regimen, and in 65% in of patients who failed to respond to
the second-line drug regimen [24].
Regarding sputum culture and drug sensitivity to second
line anti TB drugs (ciproﬂoxacin, levoﬂoxacin, amikacin, and
kanamycin), this study demonstrated drug resistance to cipro-
ﬂoxacin and levoﬂoxacin in 90% and 10% of patients of group
I versus 55% and 20% in group II. Whereas resistance to sec-
ond line injectable anti TB drugs has been encountered in
group I and group II in 0% versus 45% for amikacin and
55% versus and 65% for kanamycin. These data documentRDX
 I Group II
groups regarding the sensitivity to drugs.
Detection of extensively drug resistant pulmonary tuberculosis 645more evident drug resistance among patients of group II. In
addition, most of our studied cases have a history of receiving
repeated courses of antibiotics included in the second line anti
TB drugs, for management of respiratory or urinary tract
infections. Therefore, misuse of second-line drugs could lead
to the creation of TB strains resistant to all known anti-TB
drugs, so the emergence of XDR TB strains.
Eker et al. reported that among 184 studied patients, 174
(95%) had TB isolates resistant to streptomycin, 119 (65%)
to ethambutol, 103 (56%) to rifabutin, 79 (43%) to pyrazina-
mide, 23 (13%) to amikacin, 20 (11%) to a ﬂuoroquinolone, 19
(10%) to capreomycin, 36 (19%) to ethionamide, 15 (8%) to
para-aminosalicylic acid, 9 (5%) to cycloserine, 3 (2%) to
kanamycin, and 1 (<1%) to linezolid [17].
According to the deﬁnitions MDR-TB and XDR-TB, drug
resistance TB was detected in 20% and 60% of the studied
cases of group I and II respectively. All 20% in group I were
with MDR-TB while in group II, 25% of them were with
MDR-TB, 35% with XDR-TB. These data signify higher pro-
portion of drug resistant strains among TB cases with persis-
tent positive sputum despite anti-TB treatment than newly
diagnosed cases. Sharaf Eldin et al. in their study TB isolates
from 235 patients attending 3 treatment centers in Sudan were
screened for susceptibility to isoniazid, rifampicin, ethambutol
and streptomycin by the proportion method on LJ media.
MDR-TB was found in 5% of new cases and 24% of previ-
ously treated patients. They concluded that the high levels of
MDR observed in re-treatment patients (24%) and variation
in the prevalence of resistance across geographic regions is a
cause for concern and suggests that suboptimal treatment
has been administered [25].
The reported highest values of MDR-TB among previously
treated cases were in Oman (58.3%) and Kazakhstan (56.4%),
followed by Lithuania (53.3%), Estonia (45.3%), Tomsk
oblast in the Russian Federation (43.6%), Orel oblast in the
Russian Federation (42.4%), Karakalpakstan in Uzbekistan
(40.2%), Egypt (38.2%) and Henan in China (36.6%) [26].
The underlying biological and molecular basis of anti –TB
Drug resistance have been studied. Spontaneous chromosom-
ally borne mutations occurring in TB at a predictable rate
are thought to confer resistance to anti TB drugs. A character-
istic feature of these mutations is that they are unlinked. Thus,
resistance to a drug is usually not associated with resistance to
an unrelated drug. In a TB cavity, the probability of spontane-
ous mutations causing resistance to both isoniazid and rifam-
picin would be 106 · 108 = 1 in 1014. Given that this number
of bacilli cannot be found even in patients with extensive cav-
itatory pulmonary TB, the chance of spontaneous dual resis-
tance to rifampicin and isoniazid developing is practically
remote.(54) Moreover, TB has little opportunity to interact
and exchange genetic information with other strains compared
with, for example, organisms that colonize the nasopharynx or
the gastrointestinal tract. In these locations, other bacteria
may transmit antibiotic resistance determinants through trans-
missible genetic elements, transposons, integrons, and plas-
mids, by transduction or transformation. This option is not
available for TB. So, the primary mechanism of MDR-TB is
due to perturbations in the individual drug target genes (chro-
mosomal mutation) [23]. Furthermore, it has been described
that MDR-TB strains are often less ﬁt and less transmissible,
and outbreaks occur more readily in people with weakened im-
mune systems (e.g., patients with HIV). Outbreaks among nonimmunocompromised healthy people do occur but are less
common [23].
The above data lend support to our results regarding the
high proportion of MDR and XDR TB observed among pa-
tients with immune impairment; in 50% and 66% of DM
patients of groups I and II, patients with HIV or renal
failure.
Egypt has succeeded to achieve the global target and
occupying a place in the target zone, as published in the
Global Repot of WHO 2009 (which describes the data of
2007), to be classiﬁed as one of the 36 worldwide countries
that has achieved the global targets in both case detection
and treatment success in the year 2007. The case detection
rate of positive cases in Egypt was 72% (global target is
70%) and treatment success rate was 87% (global target is
85%). Moreover, Egypt did not stand on this, but keep
stepping ahead on the target of disease eradication to
achieve 78% case detection and 89% treatment success in
2008 [27].
The control of MDR-TB requires sound implementation
of DOTS to prevent the development of new cases, and a
careful introduction of second-line drugs with adequate lab-
oratory support to stop the ampliﬁcation and circulation of
resistant strains. The average cost of a full course of TB
treatment in Egypt is US$60 whereas a full course of
MDR-TB treatment is around US$6000. Treatment of
MDR-TB is not only more costly it is also more complex
and cure rates are low [27].
Therefore, management of MDR-TB and XDR TB is a
challenge which should be undertaken by experienced clini-
cians at centers equipped with reliable laboratory service for
mycobacterial culture and in vitro sensitivity testing as it
requires prolonged use of expensive second-line drugs with a
signiﬁcant potential for toxicity. Judicious use of drugs, super-
vised individualized treatment, focused clinical, radiological
and bacteriological follow up, use of surgery at the appropriate
juncture are key factors in the successful management of these
patients. In certain areas, currently available program ap-
proach may not be adequate and innovative approaches such
as DOTS-plus may have to be employed to effectively control
MDR-TB and XDR-TB [27].Conclusion
From the present study, these can be concluded:
1. There is relation between severity and type of TB lesion
(multiple cavitary diseases) on one hand and liability to
MDR and XDR TB on the other hand.
2. Previous anti-TB treatment was by far a strong predictor of
drug resistance.
3. DM, Drug abuse, HIV and anemia are considered to be
other risk factors for MDR-TB and XDR-TB.
4. TB patients with evidence of immune impairment are at
increased risk of emergence of MDR, XDR TB strains,
therefore they need special attention regarding measures
for prevention, rapid identiﬁcation, improved monitoring
of therapy as well as proper treatment of these situations.
5. MDR and XDR TB were more common among TB
patients with persistent positive sputum despite anti TB
treatment than newly diagnosed cases.
646 S.A. Hafez et al.6. Misuse of second-line drugs could lead to the creation of
TB strains resistant to all known anti-TB drugs with liabil-
ity of emergence of XDR TB strains.
7. Management of MDR-TB and XDR TB is a challenge
which should be undertaken by experienced clinicians at
centers equipped with reliable laboratory service for myco-
bacterial culture and in vitro sensitivity testing as it requires
prolonged use of expensive second-line drugs with a signif-
icant potential for toxicity.
8. Judicious use of drugs, supervised individualized treatment,
focused clinical, radiological and bacteriological follow up,
are key factors in the successful management of MDR and
XDR- TB patients.
9. Emergence of drug resistant TB has the potential to be a
serious public health problem in Egypt and that strength-
ened TB control and improved monitoring of therapy is
needed.
Recommendations
This research revealed many recommendations:
 More researches with larger sample sizes are needed.
 Evaluation of other risk factors as HIV, renal failure, liver
failure, drug abuse for development of MDR-TB and
XDR-TB.
 Yearly MDR-TB and XDR-TB survey is important to
monitor the problem.
 Culture and sensitivity are recommended for new smear
positive cases not converted after 2 months of treatment
and also for the contact of MDR cases.
 Usage of anti TB ﬁrst line drugs should be limited to TB
patients to decrease the incidence of resistance to these
drugs.
 Adequate period treatment and observation of TB cases are
a must to decrease the rate of resistance and transmission of
resistant strains.
 Combination of 4 or more drugs is recommended especially
during initial phase of therapy for all patients with special
emphasis on retreatment patients.
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